However, in patients with T2D, metabolic syndrome has shown to predict atherosclerosis, is an independent predictor of cardiovascular disease, is an indicator of microvascular and macrovascular complications and increased risk of adverse cardio-renal outcomes [58,59,60,61]
The dose can be increased gradually every 4 weeks up to a maximum of 2.4 mg weekly after the fifth month
LipoZome technology can be used to convert conventional pills and tablets, into liquids, sublingual sprays, and topical applications, thereby enhancing Tmax and Cpmax and overall bioavailability
Semaglutide GLP-1 is administered via subcutaneous injection, typically once a week, irrespective of meals